# Delos Capital

> Delos Capital is a VC fund in New York backing Biotechnology and Health Care. See 31 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 31
- Last investment: Jan 2026
- Lead investor: 35%
- Fund size: $275M
- Last fund: Apr 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/delos-capital
- Website: http://www.deloscap.com/

Delos Capital is a lower-middle market private equity investment firm based in New York City. The Fund was formed in 2013 to invest in complex processes through Control Buyouts, Strategic Partnerships and Distressed Buyouts in companies with EBITDA of $10 – $30 million.

## Contacts

5 contacts available for Delos Capital. Shizune tracks 3 team members at Delos Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/delos-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 48% |
| Health Care | 13 | 42% |
| Medical | 7 | 23% |
| Therapeutics | 7 | 23% |
| Pharmaceutical | 7 | 23% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 10 | 32% |
| Series A | 5 | 16% |
| Series C | 5 | 16% |
| Private Equity | 4 | 13% |
| Series D | 2 | 6% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 22 | 71% |
| China | 2 | 6% |
| Germany | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Tim Xiao | Partner | 3 | — |
| Matt Constantino | Founding Partner | 0 | — |
| Sanjay Sanghoee | CFO/COO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| STRM.BIO | STRM.BIO specializes in the fields of biotechnology and life science. | $8M | Seed | Jan 07, 2026 |  |
| Ensoma | Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $53M |  | Sep 22, 2025 |  |
| Cardurion Pharmaceuticals | Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to addressunmet patient needs. | $260M | Series B | Jul 16, 2024 |  |
| AltruBio | AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases.AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment ofcancer and immune-related inflammatory diseases.With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discovery and development of novel therapeutics for unmet medical needs.Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics.Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages. | $225M | Series B | May 21, 2024 |  |
| Zenas BioPharma | Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. | $200M | Series C | May 07, 2024 |  |
| Avenzo Therapeutics | Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $150M | Series A | Mar 26, 2024 |  |
| Instylla | Instylla’s focus is to leverage hydrogel technology . | $30M | Series C | Aug 15, 2023 |  |
| Eccogene | Eccogene is a Health Care Company. | $25.2M | Series B | Jun 12, 2023 |  |
| Ensoma | Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $50M | Series B | May 16, 2023 |  |
| Rejoni | Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $26.3M | Series B | Dec 07, 2022 |  |

10 of 31 investments shown.

## Co-investors
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 5 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 5 deals together
- [Ascension Ventures](https://shizune.co/investors/profile/ascension-ventures) — VC Fund, 4 deals together
- [AMED Ventures](https://shizune.co/investors/profile/amed-ventures) — VC Fund, 3 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 3 deals together
- [City Hill Ventures](https://shizune.co/investors/profile/city-hill-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Delos Capital invest in?

Delos Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 31 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Delos Capital?

Public channels for Delos Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Delos Capital?

The team at Delos Capital includes Tim Xiao (Partner), Matt Constantino (Founding Partner) and Sanjay Sanghoee (CFO/COO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co